Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Davidson

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Continuing Education in Nursing|July 31, 2009
Evaluation of the National Database of Nursing Quality Indicators (NDNQI) Training Program on Pressure UlcersSandra Bergquist-Beringer, Jan Davidson, Carolyn Agosto, et al.
Haematologica|July 20, 2023
Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemiaIbrahim Aldoss, Parastou Tizro, Davsheen Bedi, et al.
Research Square|August 16, 2024
Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialArmin Ghobadi, Ibrahim Aldoss, Shannon Maude, et al.
Blood|May 30, 2025
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesArmin Ghobadi, Ibrahim Aldoss, Shannon L Maude, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Continuing Education in Nursing|July 31, 2009
Evaluation of the National Database of Nursing Quality Indicators (NDNQI) Training Program on Pressure UlcersSandra Bergquist-Beringer, Jan Davidson, Carolyn Agosto, et al.
Haematologica|July 20, 2023
Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemiaIbrahim Aldoss, Parastou Tizro, Davsheen Bedi, et al.
Research Square|August 16, 2024
Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialArmin Ghobadi, Ibrahim Aldoss, Shannon Maude, et al.
Blood|May 30, 2025
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesArmin Ghobadi, Ibrahim Aldoss, Shannon L Maude, et al.
Pageof 2